{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:12:50Z","timestamp":1792897970364,"version":"4.5.0"},"reference-count":480,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1080\/17512433.2021.1878024","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T03:38:54Z","timestamp":1611545934000},"page":"179-210","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update"],"prefix":"10.1080","volume":"14","author":[{"given":"Ogugua Ndili","family":"Obi","sequence":"first","affiliation":[{"name":"Brody School of Medicine, East Carolina University","place":["Greenville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse E.","family":"Lower","sequence":"additional","affiliation":[{"name":"University of Cincinnati","place":["Cincinnati, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Baughman","sequence":"additional","affiliation":[{"name":"University of Cincinnati","place":["Cincinnati, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,1,31]]},"reference":[{"issue":"7","key":"e_1_3_3_3_1","first-page":"13","article-title":"Molecular insights into fully human and humanized monoclonal antibodies: what are the differences and should dermatologists care?","volume":"9","author":"Mallbris L","year":"2016","unstructured":"Mallbris L, Davies J, Glasebrook A, et al. Molecular insights into fully human and humanized monoclonal antibodies: what are the differences and should dermatologists care? The Journal of Clinical and Aesthetic Dermatology. 2016;9(7):13\u201315.","journal-title":"The Journal of Clinical and Aesthetic Dermatology"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.ats4-99"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.10.2104046"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201707-565OT"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018865"},{"issue":"1","key":"e_1_3_3_8_1","first-page":"61","article-title":"The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study","volume":"12","author":"Pietinalho A","year":"1995","unstructured":"Pietinalho A, Hiraga Y, Hosoda Y, et al. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis. 1995;12(1):61\u201367.","journal-title":"Sarcoidosis."},{"issue":"2","key":"e_1_3_3_9_1","first-page":"159","article-title":"The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients","volume":"13","author":"Pietinalho A","year":"1996","unstructured":"Pietinalho A, Ohmichi M, Hiraga Y, et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13(2):159\u2013166.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199704243361706"},{"issue":"2","key":"e_1_3_3_11_1","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. american thoracic society\/european respiratory society\/world association of sarcoidosis and other granulomatous disorders","volume":"16","author":"Hunninghake GW","year":"1999","unstructured":"Hunninghake GW, Costabel U, Ando M, et al. ATS\/ERS\/WASOG statement on sarcoidosis. american thoracic society\/european respiratory society\/world association of sarcoidosis and other granulomatous disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149\u2013173.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"5","key":"e_1_3_3_12_1","article-title":"Nonorgan manifestations of sarcoidosis","volume":"25","author":"Tavee J","year":"2019","unstructured":"Tavee J, Culver D. Nonorgan manifestations of sarcoidosis. Curr Opin Pulm Med. 2019;25(5):533\u2013538.","journal-title":"Curr Opin Pulm Med"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0251ST"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60680-7"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0146-2019"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0145-2019"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000612"},{"issue":"155","key":"e_1_3_3_18_1","article-title":"British thoracic society sarcoidosis study: effects of long term corticosteroid treatment.","volume":"29","author":"Gibson GJ","year":"2020","unstructured":"Gibson GJ, Prescott RJ, Muers MF, et al. British thoracic society sarcoidosis study: effects of long term corticosteroid treatment.. Thorax. 2020;29(155):190146\u2013190147.","journal-title":"Thorax."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060612"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181b97635"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.12.009"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S31064"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.12.009"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.08.012"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.09.003"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092163"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2017.10.022"},{"issue":"8","key":"e_1_3_3_28_1","article-title":"New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches","volume":"18","author":"Baughman RP","year":"2011","unstructured":"Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. The Lancet Respiratory Medicine. 2011;18(8):1306\u20131316.","journal-title":"The Lancet Respiratory Medicine"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000078"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.2174\/18715281113126660062"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9020390"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2018.09.001"},{"key":"e_1_3_3_33_1","first-page":"437","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"20","author":"Broos CE","year":"2014","unstructured":"Broos CE, van Nimwegen M, Hoogsteden HC, et al. Granuloma formation in pulmonary sarcoidosis. Frontiers in Immunology. 2014;20:437.","journal-title":"Frontiers in Immunology"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2008.03.011"},{"issue":"1","key":"e_1_3_3_35_1","first-page":"133","article-title":"Etiology of sarcoidosis: does infection play a role?","volume":"85","author":"Saidha S","year":"2012","unstructured":"Saidha S, Sotirchos ES, Eckstein C. Etiology of sarcoidosis: does infection play a role? The Yale Journal of Biology and Medicine. 2012;85(1):133\u2013141.","journal-title":"The Yale Journal of Biology and Medicine"},{"issue":"3","key":"e_1_3_3_36_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccm.2008.03.014","article-title":"The immunology of sarcoidosis","volume":"82","author":"Gerke AK","year":"2020","unstructured":"Gerke AK, Hunninghake G. The immunology of sarcoidosis. Clinics in Chest Medicine. 2020;82(3):612\u2013621.","journal-title":"Clinics in Chest Medicine"},{"issue":"5","key":"e_1_3_3_37_1","article-title":"Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics","volume":"35","author":"Iannuzzi MC","year":"2018","unstructured":"Iannuzzi MC. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA. 2018;35(5):324\u2013333.","journal-title":"JAMA."},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.140319"},{"issue":"3","key":"e_1_3_3_39_1","article-title":"The etiologic role of infectious antigens in sarcoidosis pathogenesis","volume":"6","author":"Oswald-Richter KA","year":"1965","unstructured":"Oswald-Richter KA, Drake WP. The etiologic role of infectious antigens in sarcoidosis pathogenesis. Seminars in Respiratory and Critical Care Medicine. 1965;6(3):303\u2013306.","journal-title":"Seminars in Respiratory and Critical Care Medicine"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9700-5"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid0811.020318"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200402-249OC"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-970330"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jom.0000155711.88781.91"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.1.198-204.2002"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309248"},{"issue":"3","key":"e_1_3_3_47_1","first-page":"197","article-title":"Propionibacterium acnes DNA detected in bronchoalveolar lavage cells from patients with sarcoidosis","volume":"20","author":"Hiramatsu J","year":"2003","unstructured":"Hiramatsu J, Kataoka M, Nakata Y, et al. Propionibacterium acnes DNA detected in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20(3):197\u2013203.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12411"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.12.8784"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00142-09"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-009-9311-y"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.3109\/inf.1974.6.issue-3.01"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.5.1183"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.4_Pt_1.974"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00197808"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2010-0401OC"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20143394"},{"issue":"12","key":"e_1_3_3_58_1","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.4049\/jimmunol.156.12.4952","article-title":"Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis","volume":"156","author":"Moller DR","year":"1996","unstructured":"Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol. 1996;156(12):4952\u20134960.","journal-title":"J Immunol"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.1.642"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.01.001"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2015.08.016"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8452-5"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60386-7"},{"issue":"11","key":"e_1_3_3_64_1","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.4049\/jimmunol.139.11.3680","article-title":"Internalization of interleukin 2 (IL-2) by high affinity IL-2 receptors is required for the growth of IL-2-dependent T cell lines","volume":"139","author":"Kumar A","year":"1987","unstructured":"Kumar A, Moreau JL, Gibert M, et al. Internalization of interleukin 2 (IL-2) by high affinity IL-2 receptors is required for the growth of IL-2-dependent T cell lines. J Immunol. 1987;139(11):3680\u20133684.","journal-title":"J Immunol"},{"issue":"2","key":"e_1_3_3_65_1","first-page":"122","article-title":"Biological role of the soluble interleukin-2 receptor in sarcoidosis","volume":"34","author":"Vanmaris RMM","year":"2017","unstructured":"Vanmaris RMM, Rijkers GT. Biological role of the soluble interleukin-2 receptor in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):122\u2013129.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.11.009"},{"issue":"1","key":"e_1_3_3_67_1","first-page":"41","article-title":"The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis","volume":"34","author":"Ogata-Suetsugu S","year":"2017","unstructured":"Ogata-Suetsugu S, Hamada N, Takayama K, et al. The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(1):41\u201347.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"e_1_3_3_68_1","first-page":"87","article-title":"Elevated serum levels of soluble interleukin-2 receptors in active pulmonary sarcoidosis: relative specificity and association with hypercalcemia","volume":"4","author":"Lawrence EC","year":"1987","unstructured":"Lawrence EC, Berger MB, Brousseau KP, et al. Elevated serum levels of soluble interleukin-2 receptors in active pulmonary sarcoidosis: relative specificity and association with hypercalcemia. Sarcoidosis. 1987;4(2):87\u201393.","journal-title":"Sarcoidosis"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.98.5.1125"},{"issue":"4","key":"e_1_3_3_70_1","first-page":"1128","article-title":"Soluble interleukin 2 receptors in patients with sarcoidosis","volume":"102","author":"Ina Y","year":"1992","unstructured":"Ina Y, Takada K, Sato T, et al. Soluble interleukin 2 receptors in patients with sarcoidosis. Possible Origin Chest. 1992;102(4):1128\u20131133.","journal-title":"Possible Origin Chest"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/144.6.1322"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04753"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.3.8810610"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2007.10.007"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(00)80019-0"},{"key":"e_1_3_3_77_1","first-page":"351852","article-title":"The prevalence of antinuclear antibodies in patients with sarcoidosis","volume":"2014","author":"Kobak S","year":"2014","unstructured":"Kobak S, Yilmaz H, Sever F, et al. The prevalence of antinuclear antibodies in patients with sarcoidosis. Autoimmune Dis. 2014;2014:351852.","journal-title":"Autoimmune Dis"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket186"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00049410"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcl038"},{"issue":"1","key":"e_1_3_3_81_1","first-page":"56","article-title":"Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force","volume":"28","author":"Baughman RP","year":"2011","unstructured":"Baughman RP, Nagai S, Balter M, et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(1):56\u201364.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199903000-00001"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1175301"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.080580"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050648"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.03.015"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202891"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1451OC"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.11.065"},{"issue":"2","key":"e_1_3_3_90_1","first-page":"120","article-title":"Th1 and Th2 responses regulate experimental lung granuloma development","volume":"13","author":"Kunkel SL","year":"1996","unstructured":"Kunkel SL, Lukacs NW, Strieter RM, et al. Th1 and Th2 responses regulate experimental lung granuloma development. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13(2):120\u2013128.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0696OC"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-402OC"},{"issue":"1","key":"e_1_3_3_93_1","first-page":"46","article-title":"Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis","volume":"31","author":"Sweiss NJ","year":"2014","unstructured":"Sweiss NJ, Noth I, Mirsaeidi M, et al. Efficacy results of a 52-week trial of adalimumab in the treatment of refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(1):46\u201354.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"e_1_3_3_94_1","first-page":"538","article-title":"Etanercept for chronic progressive cutaneous sarcoidosis","volume":"5","author":"Tuchinda C","year":"2006","unstructured":"Tuchinda C, Wong HK. Etanercept for chronic progressive cutaneous sarcoidosis. J Drugs Dermatol. 2006;5(6):538\u2013540.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00224513"},{"key":"e_1_3_3_96_1","first-page":"1:100004","article-title":"Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents","author":"Sharp M","year":"2019","unstructured":"Sharp M, Donnelly SC, Moller DR. Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents. Respir Med X. 2019;1:100004.","journal-title":"Respir Med X"},{"issue":"2","key":"e_1_3_3_97_1","first-page":"119","article-title":"The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States","volume":"29","author":"Judson MA","year":"2012","unstructured":"Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29(2):119\u2013127.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_98_1","first-page":"280","article-title":"The indications for the treatment of sarcoidosis: wells law","volume":"34","author":"Baughman RP","year":"2017","unstructured":"Baughman RP, Judson MA, AU W. The indications for the treatment of sarcoidosis: wells law. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34:280\u2013282.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.10.004"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201010-1679OC"},{"issue":"2","key":"e_1_3_3_101_1","first-page":"154","article-title":"Predicting respiratory failure in sarcoidosis patients","volume":"14","author":"Baughman RP","year":"1997","unstructured":"Baughman RP, Winget DB, Bowen EH, et al. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 1997;14(2):154\u2013158.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"3","key":"e_1_3_3_102_1","first-page":"275","article-title":"Causes of death in patients with chronic sarcoidosis.","volume":"33","author":"Hu X","year":"2016","unstructured":"Hu X, Carmona EM, Yi ES, et al. Causes of death in patients with chronic sarcoidosis.. Sarcoidosis Vasc Diffuse Lung Dis. 2016;33(3):275\u2013280.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"e_1_3_3_103_1","first-page":"167","article-title":"Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.","volume":"119","author":"Perry A","year":"1995","unstructured":"Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.. Archives of Pathology & Laboratory Medicine. 1995;119(2):167\u2013172.","journal-title":"Archives of Pathology & Laboratory Medicine"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.062836"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.01.019"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2016.1258061"},{"issue":"1","key":"e_1_3_3_107_1","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.","volume":"17","author":"Baughman RP","year":"2000","unstructured":"Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2000;17(1):60\u201366.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e3283642a7a"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1728"},{"issue":"1","key":"e_1_3_3_110_1","first-page":"87","article-title":"Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis.","volume":"16","author":"Lewis SJ","year":"1999","unstructured":"Lewis SJ, Ainslie GM, Bateman ED, et al. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 1999;16(1):87\u201392.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg156"},{"issue":"1","key":"e_1_3_3_112_1","first-page":"43","article-title":"Leflunomide for chronic sarcoidosis.","volume":"21","author":"Baughman RP","year":"2004","unstructured":"Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2004;21(1):43\u201348.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00195010"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1159\/000345596"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318212aafb"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.5414\/CN108025"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003431"},{"issue":"2","key":"e_1_3_3_118_1","first-page":"91","article-title":"Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis","volume":"31","author":"Drent M","year":"2014","unstructured":"Drent M, Cremers JP, sen TL, et al. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):91\u2013107.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678707.2018.1411260"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-402OC"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.03.005"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004644"},{"issue":"4","key":"e_1_3_3_123_1","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.","volume":"32","author":"Baughman RP","year":"2016","unstructured":"Baughman RP, Judson MA, Lower EE, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2016;32(4):289\u2013295.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.04.011"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.056"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2019.07.067"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418805732"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-015-0025-9"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev309"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S35521"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000914"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S192922"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.03.056"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2016.08.014"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0231-8"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-014-0237-5"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00169413"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203348"},{"issue":"1","key":"e_1_3_3_140_1","first-page":"70","article-title":"Infliximab for refractory sarcoidosis.","volume":"18","author":"Baughman RP","year":"2001","unstructured":"Baughman RP, Lower EE. Infliximab for refractory sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2001;18(1):70\u201374.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_141_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-1-200107030-00010"},{"issue":"3","key":"e_1_3_3_142_1","first-page":"201","article-title":"A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis.","volume":"23","author":"Rossman MD","year":"2006","unstructured":"Rossman MD, Newman LS, Baughman RP, et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2006;23(3):201\u2013208.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_143_1","doi-asserted-by":"publisher","DOI":"10.1159\/000328738"},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00227014"},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0873-2159(11)70020-4"},{"key":"e_1_3_3_146_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-2576"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmr.2010.06.011"},{"issue":"2","key":"e_1_3_3_148_1","first-page":"123","article-title":"18F-FDG PET as a predictor of pulmonary function in sarcoidosis.","volume":"28","author":"Keijsers RG","year":"2011","unstructured":"Keijsers RG, Verzijlbergen EJ, van den Bosch JM, et al. 18F-FDG PET as a predictor of pulmonary function in sarcoidosis.. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28(2):123\u2013129.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2002.004226"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.02.017"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00055213"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.10.008"},{"issue":"1","key":"e_1_3_3_153_1","first-page":"49","article-title":"C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis.","volume":"27","author":"Sweiss NJ","year":"2010","unstructured":"Sweiss NJ, Barnathan ES, Lo K, et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2010;27(1):49\u201356.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"issue":"1","key":"e_1_3_3_154_1","first-page":"526","article-title":"Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation","volume":"16","author":"Baughman RP","year":"1999","unstructured":"Baughman RP, Shipley R, Desai S, et al. Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest. 1999;16(1):526\u2013535.","journal-title":"Chest."},{"issue":"5","key":"e_1_3_3_155_1","article-title":"Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial","volume":"86","author":"Judson MA","year":"2013","unstructured":"Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. European Respiratory Journal. 2013;86(5):376\u2013383.","journal-title":"European Respiratory Journal"},{"issue":"13","key":"e_1_3_3_156_1","first-page":"1093","article-title":"Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety","volume":"76","author":"Adler BL","year":"2011","unstructured":"Adler BL, Wang CJ, Bui T-L, et al. Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Semin Arthritis Rheum. 2011;76(13):1093\u20131104.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"e_1_3_3_157_1","first-page":"S47","article-title":"Tumor necrosis factor inhibition in treating sarcoidosis: the American experience","volume":"174","author":"Baughman RP","year":"2006","unstructured":"Baughman RP. Tumor necrosis factor inhibition in treating sarcoidosis: the American experience. Revista Portuguesa de. 2006;Pneumologia 174(7):S47\u2013S50.","journal-title":"Revista Portuguesa de"},{"key":"e_1_3_3_158_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2009.01518.x"},{"issue":"4","key":"e_1_3_3_159_1","first-page":"509","article-title":"Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases.","volume":"33","author":"Chapelon-Abric C","year":"2015","unstructured":"Chapelon-Abric C, Saadoun D, Biard L, et al. Long-term outcome of infliximab in severe chronic and refractory systemic sarcoidosis: a report of 16 cases.. Clinical and Experimental Rheumatology. 2015;33(4):509\u2013515.","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_3_3_160_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-1347"},{"key":"e_1_3_3_161_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.1162"},{"key":"e_1_3_3_162_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21468"},{"key":"e_1_3_3_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.08.016"},{"key":"e_1_3_3_164_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000341278.26993.22"},{"issue":"6","key":"e_1_3_3_165_1","article-title":"Treatment of refractory neurosarcoidosis with Infliximab","volume":"43","author":"Santos E","year":"2014","unstructured":"Santos E, Shaunak S, Renowden S, et al. Treatment of refractory neurosarcoidosis with Infliximab. Journal of Neurology, Neurosurgery & Psychiatry. 2014;43(6):1730\u20131739.","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"2","key":"e_1_3_3_166_1","first-page":"275","article-title":"Anti-TNF-\u03b1 therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review.","volume":"32","author":"Riancho-Zarrabeitia L","year":"2014","unstructured":"Riancho-Zarrabeitia L, Delgado-Alvarado M, Riancho J, et al. Anti-TNF-\u03b1 therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review.. Clin Exp Rheumatol. 2014;32(2):275\u2013284.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_167_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000847"},{"issue":"1","key":"e_1_3_3_168_1","first-page":"891","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"43","author":"Cohen Aubart F","year":"2013","unstructured":"Cohen Aubart F, Bouvry D, Galanaud D, et al. Long-term outcomes of refractory neurosarcoidosis treated with infliximab. Journal of Neurology. 2013;43(1):891\u2013897.","journal-title":"Journal of Neurology"},{"issue":"2","key":"e_1_3_3_169_1","article-title":"Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients","volume":"136","author":"Riancho-Zarrabeitia L","year":"2009","unstructured":"Riancho-Zarrabeitia L, Calvo-R\u00edo V, Blanco R, et al. Anti-TNF-\u03b1 therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients. Semin Arthritis Rheum. 2009;136(2):526\u2013535.","journal-title":"Semin Arthritis Rheum"},{"key":"e_1_3_3_170_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP43007"},{"issue":"1","key":"e_1_3_3_171_1","first-page":"26","article-title":"Management of ocular sarcoidosis.","volume":"29","author":"Baughman RP","year":"2012","unstructured":"Baughman RP, Lower EE, Ingledue R, et al. Management of ocular sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2012;29(1):26\u201333.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_172_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39667"},{"key":"e_1_3_3_173_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4228-6"},{"issue":"4","key":"e_1_3_3_174_1","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"14","author":"Mann DL","year":"2009","unstructured":"Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2009;14(4):522\u2013528.","journal-title":"Circulation."},{"key":"e_1_3_3_175_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000077913.60364.D2"},{"key":"e_1_3_3_176_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0614-1"},{"issue":"8","key":"e_1_3_3_177_1","first-page":"1686","article-title":"Successful treatment of cardiac sarcoidosis with infliximab.","volume":"35","author":"Barnabe C","year":"2008","unstructured":"Barnabe C, McMeekin J, Howarth A, et al. Successful treatment of cardiac sarcoidosis with infliximab.. The Journal of Rheumatology. 2008;35(8):1686\u20131687.","journal-title":"The Journal of Rheumatology"},{"key":"e_1_3_3_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.02.004"},{"key":"e_1_3_3_179_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.3.1064"},{"key":"e_1_3_3_180_1","first-page":"135","article-title":"Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment","volume":"41","author":"Tavee JO","year":"2013","unstructured":"Tavee JO, Karwa K, Ahmed Z, et al. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIG and anti-TNF alpha treatment. Respiratory Medicine. 2013;41:135\u2013138.","journal-title":"Respiratory Medicine"},{"issue":"13","key":"e_1_3_3_181_1","article-title":"Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab.","volume":"109","author":"Hoitsma E","year":"2004","unstructured":"Hoitsma E, Faber CG, Reulen JPH, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab.. Circulation. 2004;109(13):1594\u20131602.","journal-title":"Circulation"},{"key":"e_1_3_3_182_1","doi-asserted-by":"publisher","DOI":"10.1159\/000314225"},{"key":"e_1_3_3_183_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1602589"},{"key":"e_1_3_3_184_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1710080"},{"key":"e_1_3_3_185_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.12.006"},{"issue":"1","key":"e_1_3_3_186_1","first-page":"76","article-title":"Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.","volume":"42","author":"Baughman RP","year":"2012","unstructured":"Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.. Sarcoidosis, Vasculitis, and Diffuse Lung diseases : Official Journal of WASOG. 2012;42(1):76\u201389.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung diseases : Official Journal of WASOG"},{"issue":"2","key":"e_1_3_3_187_1","first-page":"54","article-title":"Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET\/CT: sUVmax versus total lung glycolysis","volume":"25","author":"Schimmelpennink MC","year":"2008","unstructured":"Schimmelpennink MC, Vorselaars ADM, Veltkamp M, et al. Quantification of pulmonary disease activity in sarcoidosis measured with 18F-FDG PET\/CT: sUVmax versus total lung glycolysis. EJNMMI Research. 2008;25(2):54.","journal-title":"EJNMMI Research"},{"issue":"1","key":"e_1_3_3_188_1","first-page":"46","article-title":"A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the british thoracic society study of long-term corticosteroid treatment.","volume":"14","author":"Muers MF","year":"1997","unstructured":"Muers MF, Middleton WG, Gibson GJ, et al. A simple radiographic scoring method for monitoring pulmonary sarcoidosis: relations between radiographic scores, dyspnoea grade and respiratory function in the british thoracic society study of long-term corticosteroid treatment.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 1997;14(1):46\u201356.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_189_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.11.019"},{"key":"e_1_3_3_190_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.2009.01437.x"},{"key":"e_1_3_3_191_1","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1997.0224"},{"issue":"5","key":"e_1_3_3_192_1","article-title":"Use of third-line therapies in advanced sarcoidosis","volume":"38","author":"Lower EE","year":"2019","unstructured":"Lower EE, Sturdivant M, Grate L, et al. Use of third-line therapies in advanced sarcoidosis. Clin Exp Rheumatol. 2019;38(5):834\u2013840.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"e_1_3_3_193_1","first-page":"275","article-title":"Features of sarcoidosis associated with chronic disease.","volume":"31","author":"Baughman RP","year":"2015","unstructured":"Baughman RP, Lower EE. Features of sarcoidosis associated with chronic disease.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2015;31(4):275\u2013281.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_194_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.111.3.623"},{"issue":"4","key":"e_1_3_3_195_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/injr.injr_102_19","article-title":"Experience of sarcoidosis and factors predicting relapse at a tertiary care institute in North India","volume":"14","author":"Alok N","year":"2019","unstructured":"Alok N, Zia H, Ajmal K, et al. Experience of sarcoidosis and factors predicting relapse at a tertiary care institute in North India. Indian J Rheumatol. 2019;14(4):265\u2013270.","journal-title":"Indian J Rheumatol"},{"key":"e_1_3_3_196_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt.14.65"},{"key":"e_1_3_3_197_1","doi-asserted-by":"publisher","DOI":"10.12703\/P6-89"},{"key":"e_1_3_3_198_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2011.00276.x"},{"key":"e_1_3_3_199_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1844-0"},{"key":"e_1_3_3_200_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010952"},{"key":"e_1_3_3_201_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1491605"},{"key":"e_1_3_3_202_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509852"},{"key":"e_1_3_3_203_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4133-z"},{"key":"e_1_3_3_204_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1623847"},{"key":"e_1_3_3_205_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4069-3"},{"key":"e_1_3_3_206_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001124"},{"key":"e_1_3_3_207_1","doi-asserted-by":"publisher","DOI":"10.4076\/1752-1947-3-8573"},{"key":"e_1_3_3_208_1","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e3181dc9a54"},{"key":"e_1_3_3_209_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.184.10.1214"},{"key":"e_1_3_3_210_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04964-1"},{"key":"e_1_3_3_211_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S44542"},{"issue":"4","key":"e_1_3_3_212_1","first-page":"254","article-title":"Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome.","volume":"36","author":"Lower EE","year":"2019","unstructured":"Lower EE, Sturdivant M, Baughman RP. Presence of onconeural antibodies in sarcoidosis patients with parasarcoidosis syndrome.. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(4):254\u2013260.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_213_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.1.177"},{"key":"e_1_3_3_214_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0012-3692(15)50471-6"},{"key":"e_1_3_3_215_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28674"},{"key":"e_1_3_3_216_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200110000-00023"},{"key":"e_1_3_3_217_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-005-0059-y"},{"key":"e_1_3_3_218_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/724013"},{"key":"e_1_3_3_219_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181efa190"},{"issue":"3","key":"e_1_3_3_220_1","first-page":"378","article-title":"Sarcoidosis-like lesions: another paradoxical reaction to Anti-TNF Therapy?","volume":"11","author":"ock A","year":"2017","unstructured":"ock A, Van Assche G, Vermeire S, et al. Sarcoidosis-like lesions: another paradoxical reaction to Anti-TNF Therapy? J Crohns Colitis. 2017;11(3):378\u2013383.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"e_1_3_3_221_1","first-page":"609","article-title":"Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors.","volume":"11","author":"Cathcart S","year":"2012","unstructured":"Cathcart S, Sami N, Elewski B. Sarcoidosis as an adverse effect of tumor necrosis factor inhibitors.. Journal of Drugs in Dermatology : JDD. 2012;11(5):609\u2013612.","journal-title":"Journal of Drugs in Dermatology : JDD"},{"key":"e_1_3_3_222_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-009-0691-6"},{"issue":"2","key":"e_1_3_3_223_1","first-page":"178","article-title":"Sarcoidosis during etanercept treatment for rheumatoid arthritis in women with a history of bilateral oophorectomy.","volume":"33","author":"Sawahata M","year":"2016","unstructured":"Sawahata M, Sigiyama Y, Yamasawa H, et al. Sarcoidosis during etanercept treatment for rheumatoid arthritis in women with a history of bilateral oophorectomy.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2016;33(2):178\u2013181.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_224_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1577-1"},{"key":"e_1_3_3_225_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.05.001"},{"key":"e_1_3_3_226_1","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1136\/bcr-2014-208188","article-title":"A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature.","volume":"2015","author":"Berrios I","year":"2015","unstructured":"Berrios I, Jun-O\u2019Connell A, Ghiran S, et al. A case of neurosarcoidosis secondary to treatment of etanercept and review of the literature.. BMJ Case Reports. 2015;2015:2015.","journal-title":"BMJ Case Reports"},{"key":"e_1_3_3_227_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-212"},{"key":"e_1_3_3_228_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20132588"},{"key":"e_1_3_3_229_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2012.05.001"},{"key":"e_1_3_3_230_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmr.2013.04.029"},{"key":"e_1_3_3_231_1","doi-asserted-by":"publisher","DOI":"10.2169\/naika.104.769"},{"key":"e_1_3_3_232_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep046"},{"key":"e_1_3_3_233_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2011.02612.x"},{"key":"e_1_3_3_234_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1372421"},{"key":"e_1_3_3_235_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2008.09.008"},{"key":"e_1_3_3_236_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.11.028"},{"issue":"2","key":"e_1_3_3_237_1","first-page":"344","article-title":"Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis.","volume":"37","author":"Toussirot E","year":"2019","unstructured":"Toussirot E, Bernard C, Bossert M. Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis.. Clinical and Experimental Rheumatology. 2019;37(2):344\u2013345.","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_3_3_238_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4275-19"},{"issue":"2","key":"e_1_3_3_239_1","first-page":"87","article-title":"Infection prevention in sarcoidosis:proposal for vaccination and prophylactic therapy","volume":"37","author":"Syed H","year":"2020","unstructured":"Syed H, Ascoli C, Linssen CF, et al. Infection prevention in sarcoidosis:proposal for vaccination and prophylactic therapy. Sarcoidosis Vasculitis Diffuse Lung Dis. 2020;37(2):87\u201398.","journal-title":"Sarcoidosis Vasculitis Diffuse Lung Dis"},{"key":"e_1_3_3_240_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.08.048"},{"issue":"4","key":"e_1_3_3_241_1","first-page":"280","article-title":"Infliximab or biosimilars in sarcoidosis; to switch or not to switch?","volume":"32","author":"Veltkamp M","year":"2016","unstructured":"Veltkamp M, Drent M, Baughman RP. Infliximab or biosimilars in sarcoidosis; to switch or not to switch? Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2016;32(4):280\u2013283.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_242_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S236433"},{"key":"e_1_3_3_243_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203090"},{"key":"e_1_3_3_244_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208786"},{"key":"e_1_3_3_245_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5"},{"key":"e_1_3_3_246_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09234-y"},{"key":"e_1_3_3_247_1","first-page":"S7","article-title":"Efficacy and safety of infliximab biosimilar","volume":"138","author":"Schimmelpennink MC","year":"2018","unstructured":"Schimmelpennink MC, Vorselaars ADM, van Beek FT, et al. Efficacy and safety of infliximab biosimilar. Inflectra\u00ae in Severe Sarcoidosis. Respiratory Medicine. 2018 ;138:S7\u2013S13.","journal-title":"Inflectra\u00ae in Severe Sarcoidosis. Respiratory Medicine"},{"key":"e_1_3_3_248_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00418"},{"key":"e_1_3_3_249_1","doi-asserted-by":"publisher","DOI":"10.1097\/CPM.0000000000000136"},{"key":"e_1_3_3_250_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-017-9994-4"},{"key":"e_1_3_3_251_1","doi-asserted-by":"publisher","DOI":"10.1177\/1753466619888127"},{"issue":"5","key":"e_1_3_3_252_1","article-title":"Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.","volume":"250","author":"Drake WP","year":"2012","unstructured":"Drake WP, Richmond BW, Oswald-Richter K, et al. Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung diseases : Official Journal of WASOG. 2012;250(5):713\u2013720.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung diseases : Official Journal of WASOG"},{"key":"e_1_3_3_253_1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199755691.003.0175"},{"issue":"2","key":"e_1_3_3_254_1","article-title":"Resolution of chronic ocular sarcoidosis with antimycobacterial therapy","volume":"1","author":"Richmond BW","year":"2014","unstructured":"Richmond BW, Richter K, King LE, et al. Resolution of chronic ocular sarcoidosis with antimycobacterial therapy. Case Rep Intern Med. 2014;1(2):5042.","journal-title":"Case Rep Intern Med"},{"issue":"5","key":"e_1_3_3_255_1","first-page":"86","article-title":"Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes","volume":"124","author":"Hunninghake GW","year":"2011","unstructured":"Hunninghake GW, Crystal RG. Mechanisms of hypergammaglobulinemia in pulmonary sarcoidosis. Site of increased antibody production and role of T lymphocytes. Journal of Clinical Investigation. 2011;124(5):86\u201392.","journal-title":"Journal of Clinical Investigation"},{"issue":"3","key":"e_1_3_3_256_1","first-page":"S7","article-title":"Systemic immune response of patients with active pulmonary sarcoidosis.","volume":"138","author":"Baughman RP","year":"2018","unstructured":"Baughman RP, Hurtubise PE. Systemic immune response of patients with active pulmonary sarcoidosis.. Clinical and Experimental Immunology. 2018;138(3):S7\u2013S13.","journal-title":"Clinical and Experimental Immunology"},{"key":"e_1_3_3_257_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.74.3.261"},{"key":"e_1_3_3_258_1","doi-asserted-by":"publisher","DOI":"10.1159\/000195495"},{"issue":"2","key":"e_1_3_3_259_1","article-title":"Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis","volume":"23","author":"Lee N-S","year":"2016","unstructured":"Lee N-S, Barber L, Akula SM, et al. Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clinical and Vaccine Immunology. 2016;23(2):67\u201375.","journal-title":"Clinical and Vaccine Immunology"},{"issue":"3","key":"e_1_3_3_260_1","first-page":"e43588","article-title":"Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels","volume":"30","author":"Saussine A","year":"2013","unstructured":"Saussine A, Tazi A, Feuillet S, et al. Active chronic sarcoidosis is characterized by increased transitional blood B cells, increased IL-10-producing regulatory B cells and high BAFF levels. PLoS One. 2013;30(3):e43588.","journal-title":"PLoS One"},{"key":"e_1_3_3_261_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"#cr-split#-e_1_3_3_262_1.1","unstructured":"US National Library of Medicine. RITUXAN - rituximab 2020 [updated March 24 2020"},{"key":"#cr-split#-e_1_3_3_262_1.2","unstructured":"[cited 2020 September 10]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563"},{"key":"e_1_3_3_263_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20689"},{"key":"e_1_3_3_264_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12793"},{"key":"e_1_3_3_265_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.762982"},{"key":"e_1_3_3_266_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.01.025"},{"key":"e_1_3_3_267_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2009.11.005"},{"key":"e_1_3_3_268_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7ff9"},{"key":"e_1_3_3_269_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000900"},{"key":"e_1_3_3_270_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2012.09.030"},{"key":"e_1_3_3_271_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150051"},{"key":"e_1_3_3_272_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2017.3143"},{"key":"e_1_3_3_273_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13693"},{"key":"e_1_3_3_274_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-37-4-776"},{"key":"e_1_3_3_275_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.29.3.277"},{"key":"e_1_3_3_276_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2015.11.007"},{"key":"e_1_3_3_277_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmcr.2015.11.001"},{"key":"e_1_3_3_278_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2015.02.003"},{"key":"e_1_3_3_279_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00021"},{"key":"e_1_3_3_280_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.2001.01022.x"},{"key":"e_1_3_3_281_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.72.5.946"},{"key":"e_1_3_3_282_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0147-2019"},{"key":"e_1_3_3_283_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04109-6"},{"key":"e_1_3_3_284_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1297"},{"issue":"1","key":"e_1_3_3_285_1","first-page":"187","article-title":"The promise of jak inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the Literature","volume":"93","author":"Wang A","year":"2020","unstructured":"Wang A, Singh K, Ibrahim W, et al. The promise of jak inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the Literature. Yale J Biol Med. 2020;93(1):187\u2013195.","journal-title":"Yale J Biol Med"},{"key":"e_1_3_3_286_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.04.010"},{"key":"e_1_3_3_287_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"e_1_3_3_288_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1202117"},{"key":"e_1_3_3_289_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1119(02)00398-0"},{"key":"e_1_3_3_290_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273941003797934"},{"key":"e_1_3_3_291_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805958"},{"key":"e_1_3_3_292_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.098"},{"key":"e_1_3_3_293_1","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5RI0218-084R"},{"key":"e_1_3_3_294_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key256"},{"key":"e_1_3_3_295_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28441"},{"key":"e_1_3_3_296_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01482-2018"},{"key":"e_1_3_3_297_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.02.006"},{"key":"e_1_3_3_298_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215387"},{"key":"e_1_3_3_299_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11112"},{"key":"e_1_3_3_300_1","article-title":"Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis.","author":"Sejournet L","year":"2020","unstructured":"Sejournet L, Kodjikian L, Grange L, et al. Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis.. Clinical and Experimental Rheumatology. 2020 June 30.","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_3_3_301_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.098"},{"key":"e_1_3_3_302_1","unstructured":"ClinicalTrials.gov. Tofacitinib hypothesis-generating pilot study for corticosteroid-dependent sarcoidosis 2019 [cited 2020 Sept 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03793439"},{"key":"e_1_3_3_303_1","unstructured":"ClinicalTrials.gov. Open-label trial of tofacitinib in cutaneous sarcoidosis and granuloma annulare 2019 [cited 2020 Sept 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03910543"},{"key":"e_1_3_3_304_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez087"},{"issue":"17","key":"e_1_3_3_305_1","first-page":"362","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"11","author":"Strand V","year":"2018","unstructured":"Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Research & Therapy. 2018;11(17):362.","journal-title":"Arthritis Research & Therapy"},{"key":"e_1_3_3_306_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40187"},{"key":"e_1_3_3_307_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.106.1.156"},{"key":"e_1_3_3_308_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.d01-905.x"},{"key":"e_1_3_3_309_1","first-page":"3787","article-title":"TNF-\u03b1, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course","volume":"42","author":"Denisova O","year":"2013","unstructured":"Denisova O, Egorova K, Chernogoryuk G. TNF-\u03b1, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course. Eur Respir J. 2013;42:3787.","journal-title":"Eur Respir J"},{"key":"e_1_3_3_310_1","volume-title":"The cerebrospinal fluid CD4\/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter","author":"Chazal T","year":"2019","unstructured":"Chazal T, Costopoulos M, Maillart E, et al. The cerebrospinal fluid CD4\/CD8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter. comparative study. Eur J Neurol: pragmatic; 2019."},{"key":"e_1_3_3_311_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.93"},{"key":"e_1_3_3_312_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.08.018"},{"issue":"3","key":"e_1_3_3_313_1","first-page":"491","article-title":"Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis","volume":"104","author":"Terabe F","year":"2018","unstructured":"Terabe F, Fujimoto M, Serada S, et al. Comparative analysis of the effects of anti-IL-6 receptor mAb and anti-TNF mAb treatment on CD4+ T-cell responses in murine colitis. Inflamm Bowel Dis. 2018;104(3):491\u2013502.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"e_1_3_3_314_1","first-page":"307","article-title":"Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics\/pharmacodynamics and clinical efficacy","volume":"52","author":"Song S-NJ","year":"2018","unstructured":"Song S-NJ, Yoshizaki K. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics\/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism & Toxicology. 2018;52(6):307\u2013316.","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"e_1_3_3_315_1","first-page":"1593","article-title":"Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib","volume":"78","author":"Raimondo MG","year":"2019","unstructured":"Raimondo MG, Biggioggero M, Crotti C, et al. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Annals of the Rheumatic Diseases. 2019;78:1593\u20131603.","journal-title":"Annals of the Rheumatic Diseases"},{"key":"e_1_3_3_316_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-017-0292-6"},{"key":"e_1_3_3_317_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-015-0569-8"},{"key":"e_1_3_3_318_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620716653745"},{"key":"e_1_3_3_319_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0320-3"},{"key":"e_1_3_3_320_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4006-5"},{"key":"e_1_3_3_321_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13015"},{"key":"e_1_3_3_322_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19841796"},{"key":"e_1_3_3_323_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130278"},{"issue":"4","key":"e_1_3_3_324_1","first-page":"716","article-title":"Sarcoidosis and tocilizumab: is there a link?","volume":"35","author":"Bustamente L","year":"2017","unstructured":"Bustamente L, Buscot M, Marquette C-H, et al. Sarcoidosis and tocilizumab: is there a link? Clinical and Experimental Rheumatology. 2017;35(4):716.","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_3_3_325_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14268"},{"key":"e_1_3_3_326_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14909"},{"key":"e_1_3_3_327_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.1.227"},{"issue":"1","key":"e_1_3_3_328_1","first-page":"51","article-title":"The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis.","volume":"23","author":"Judson MA","year":"2006","unstructured":"Judson MA, Silvestri J, Hartung C, et al. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2006;23(1):51\u201357.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_329_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2012.03.005"},{"key":"e_1_3_3_330_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-0015"},{"key":"e_1_3_3_331_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.07.006"},{"key":"e_1_3_3_332_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.301"},{"key":"e_1_3_3_333_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.155.5.9154873"},{"issue":"2","key":"e_1_3_3_334_1","first-page":"121","article-title":"Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.","volume":"26","author":"Park MK","year":"2009","unstructured":"Park MK, Fontana F, Babaali H, et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis.. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG. 2009;26(2):121\u2013131.","journal-title":"Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG"},{"key":"e_1_3_3_335_1","first-page":"A4754","article-title":"Roflumilast Reduces Circulatory IL-17 Levels in Sarcoidosis Subjects with Pulmonary Fibrosis","volume":"195","author":"Schweitzer M","year":"2017","unstructured":"Schweitzer M, Mirsaeidi M, Campos M, et al. Roflumilast Reduces Circulatory IL-17 Levels in Sarcoidosis Subjects with Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017;195:A4754.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_3_336_1","first-page":"A4752","article-title":"A double Blind, Placebo Controlled Study of Roflumilast to Prevent Acute Events in Fibrotic Sarcoidosis","volume":"195","author":"Baughman P","year":"2017","unstructured":"Baughman P, Birring S, Judson MA, et al. A double Blind, Placebo Controlled Study of Roflumilast to Prevent Acute Events in Fibrotic Sarcoidosis. Am J Respiratory Crit Care Med. 2017;195:A4752.","journal-title":"Am J Respiratory Crit Care Med"},{"key":"e_1_3_3_337_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06747.x"},{"key":"e_1_3_3_338_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196563303"},{"key":"e_1_3_3_339_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1980.tb00342.x"},{"key":"e_1_3_3_340_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(97)90134-7"},{"issue":"15","key":"e_1_3_3_341_1","first-page":"963","article-title":"Cutaneous sarcoidosis. Treatment with thalidomide","volume":"12","author":"Barriere H","year":"1983","unstructured":"Barriere H. Cutaneous sarcoidosis. Treatment with thalidomide. Presse Med. 1983;12(15):963.","journal-title":"Presse Med"},{"key":"e_1_3_3_342_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)91549-4"},{"key":"e_1_3_3_343_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70360-3"},{"key":"e_1_3_3_344_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.8.1045"},{"key":"e_1_3_3_345_1","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-2-27"},{"key":"e_1_3_3_346_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3102115"},{"key":"e_1_3_3_347_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.05.014"},{"key":"e_1_3_3_348_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0218-4"},{"issue":"4","key":"e_1_3_3_349_1","first-page":"719","article-title":"Regulation of tumour necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP.","volume":"64","author":"Katakami Y","year":"2020","unstructured":"Katakami Y, Nakao Y, Koizumi T, et al. Regulation of tumour necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP.. Immunology. 2020;64(4):719\u2013724.","journal-title":"Immunology."},{"key":"e_1_3_3_350_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)60727-6"},{"key":"e_1_3_3_351_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00559.x"},{"key":"e_1_3_3_352_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X10381432"},{"key":"e_1_3_3_353_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(94)70069-9"},{"key":"e_1_3_3_354_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1997.00252.x"},{"key":"e_1_3_3_355_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(88)81271-3"},{"issue":"7","key":"e_1_3_3_356_1","first-page":"415","article-title":"[Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline].","volume":"26","author":"Tong Z-H","year":"2003","unstructured":"Tong Z-H, Dai H-P, Chen B-M, et al. [Inhibition of cytokine release from alveolar macrophages in pulmonary sarcoidosis by pentoxifylline].. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases. 2003;26(7):415\u2013418.","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases"},{"key":"e_1_3_3_357_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.2.9804085"},{"issue":"3","key":"e_1_3_3_358_1","first-page":"107","article-title":"[Pentoxifylline inhibits secretion of O2- and TNF-alpha by alveolar macrophages in patients with sarcoidosis]","volume":"23","author":"Korber M","year":"1995","unstructured":"Korber M, Kamp S, Kothe H, et al. [Pentoxifylline inhibits secretion of O2- and TNF-alpha by alveolar macrophages in patients with sarcoidosis]. Immunitat und Infektion. 1995;23(3):107\u2013110.","journal-title":"Immunitat und Infektion"},{"issue":"4","key":"e_1_3_3_359_1","first-page":"520","article-title":"Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity","volume":"78","author":"Semmler J","year":"1993","unstructured":"Semmler J, Gebert U, Eisenhut T, et al. Xanthine derivatives: comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology. 1993;78(4):520\u2013525.","journal-title":"Immunology."},{"key":"#cr-split#-e_1_3_3_360_1.1","unstructured":"U.S. National Library of Medicine . daliresp- roflumilast tablet 2020 [updated March 12 2020"},{"key":"#cr-split#-e_1_3_3_360_1.2","unstructured":"cited 2020 september 7]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c9a1d0a8-581f-4f91-a2b8-f419192d0ebf"},{"issue":"2","key":"e_1_3_3_361_1","article-title":"Role of vasoactive intestinal peptide in inflammation and autoimmunity.","volume":"17","author":"Gonzalez-Rey E","year":"2011","unstructured":"Gonzalez-Rey E, Delgado M. Role of vasoactive intestinal peptide in inflammation and autoimmunity. Current Opinion in Investigational Drugs (London, England : 2000). 2011;17(2):491\u2013502.","journal-title":"Current Opinion in Investigational Drugs (London, England : 2000)"},{"key":"e_1_3_3_362_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-001-0291-5"},{"key":"e_1_3_3_363_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0605299"},{"issue":"6","key":"e_1_3_3_364_1","article-title":"Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis","volume":"32","author":"Gonzalez-Rey E","year":"2018","unstructured":"Gonzalez-Rey E, Fernandez-Martin A, Chorny A, et al. Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum. 2018;32(6):531\u2013546.","journal-title":"Arthritis Rheum"},{"key":"e_1_3_3_365_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.017"},{"key":"e_1_3_3_366_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01355"},{"issue":"7","key":"e_1_3_3_367_1","article-title":"A functional interleukin 12 receptor complex is composed of two -type cytokine receptor subunits","volume":"59","author":"Presky DH","year":"2020","unstructured":"Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two -type cytokine receptor subunits. Proc Natl Acad Sci U S A. 2020;59(7):888\u2013889.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_3_368_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00070-4"},{"issue":"2","key":"e_1_3_3_369_1","article-title":"Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells","volume":"50","author":"Macatonia SE","year":"2004","unstructured":"Macatonia SE, Hosken NA, Litton M, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. 2004;50(2):235\u2013241.","journal-title":"J Immunol"},{"key":"e_1_3_3_370_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801603"},{"issue":"2","key":"e_1_3_3_371_1","article-title":"Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis","volume":"153","author":"Shigehara K","year":"2005","unstructured":"Shigehara K, Shijubo N, Ohmichi M, et al. Increased circulating interleukin-12 (IL-12) p40 in pulmonary sarcoidosis. Clin Exp Immunol. 2005;153(2):254\u2013257.","journal-title":"Clin Exp Immunol"},{"key":"e_1_3_3_372_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.46.6278"},{"key":"e_1_3_3_373_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker316"},{"key":"e_1_3_3_374_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9817-6"},{"key":"#cr-split#-e_1_3_3_375_1.1","unstructured":"US National Library of Medicine. Stelara (ustekinumab) injection solution (ssen Biotech Inc.) 2020 [updated August 4 2020"},{"key":"#cr-split#-e_1_3_3_375_1.2","unstructured":"cited 2020 September 7]. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=c77a9664-e3bb-4023-b400-127aa53bca2b#S14.5"},{"key":"e_1_3_3_376_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12942"},{"key":"e_1_3_3_377_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3893"},{"key":"e_1_3_3_378_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-101011-155745"},{"key":"e_1_3_3_379_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.09.005"},{"key":"e_1_3_3_380_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.04.007"},{"key":"e_1_3_3_381_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29268"},{"key":"e_1_3_3_382_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.315937"},{"key":"e_1_3_3_383_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy128"},{"key":"e_1_3_3_384_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00119-2019"},{"key":"e_1_3_3_385_1","doi-asserted-by":"publisher","DOI":"10.1155\/S0962935192000474"},{"key":"e_1_3_3_386_1","doi-asserted-by":"publisher","DOI":"10.1159\/000236532"},{"issue":"3","key":"e_1_3_3_387_1","first-page":"629","article-title":"Direct evidence for granuloma-inducing activity of interleukin-1. Induction of experimental pulmonary granuloma formation in mice by interleukin-1-coupled beads.","volume":"130","author":"Kasahara K","year":"1988","unstructured":"Kasahara K, Kobayashi K, Shikama Y, et al. Direct evidence for granuloma-inducing activity of interleukin-1. Induction of experimental pulmonary granuloma formation in mice by interleukin-1-coupled beads.. The American Journal of Pathology. 1988;130(3):629\u2013638.","journal-title":"The American Journal of Pathology"},{"key":"e_1_3_3_388_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.119.007582"},{"key":"e_1_3_3_389_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014941"},{"key":"e_1_3_3_390_1","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000847"},{"key":"e_1_3_3_391_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvx018"},{"issue":"7","key":"e_1_3_3_392_1","article-title":"Interleukin-1 Blockade in Acute Decompensated Heart Failure","volume":"26","author":"Van Tassell BW","year":"2003","unstructured":"Van Tassell BW, Abouzaki NA, Oddi Erdle C, et al. Interleukin-1 Blockade in Acute Decompensated Heart Failure. J Cardiovasc Pharmacol. 2003;26(7):415\u2013418.","journal-title":"J Cardiovasc Pharmacol"},{"key":"e_1_3_3_393_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"e_1_3_3_394_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.123885"},{"key":"e_1_3_3_395_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.530653"},{"key":"e_1_3_3_396_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27600"},{"key":"#cr-split#-e_1_3_3_397_1.1","unstructured":"US National Library of Medicine. Study of Efficacy Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis 2016 [updated March 16 2020"},{"key":"#cr-split#-e_1_3_3_397_1.2","unstructured":"cited 2020 September 21]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02888080"},{"key":"e_1_3_3_398_1","unstructured":"US National Library of Medicine. Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis (MAGiC-ART): US National Library of Medicine; 2019 [updated September 1 2020; cited 2020 September 22]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04017936?term=anakinra&cond=Sarcoidosis&cntry=US&draw=2&rank=1"},{"key":"e_1_3_3_399_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes377"},{"key":"e_1_3_3_400_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.03.007"},{"key":"e_1_3_3_401_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030649"},{"key":"e_1_3_3_402_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.8.4718"},{"key":"e_1_3_3_403_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.08.019"},{"key":"e_1_3_3_404_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2006.26.400"},{"issue":"6","key":"e_1_3_3_405_1","first-page":"507","article-title":"Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis","volume":"59","author":"Mroz RM","year":"2008","unstructured":"Mroz RM, Korniluk M, Stasiak-Barmuta A, et al. Increased levels of interleukin-12 and interleukin-18 in bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis. J Physiol Pharmacol. 2008;59(Suppl 6):507\u2013513.","journal-title":"J Physiol Pharmacol"},{"key":"e_1_3_3_406_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.5.9911113"},{"key":"e_1_3_3_407_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1688"},{"key":"e_1_3_3_408_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.565"},{"key":"e_1_3_3_409_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1202947"},{"key":"e_1_3_3_410_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201503-0635LE"},{"issue":"1","key":"e_1_3_3_411_1","first-page":"27","article-title":"Cytotoxic T-lymphocyte antigen 4 gene polymorphisms in sarcoidosis patients","volume":"22","author":"Hattori N","year":"2005","unstructured":"Hattori N, Niimi T, Sato S, et al. Cytotoxic T-lymphocyte antigen 4 gene polymorphisms in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22(1):27\u201332.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_412_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0455-8"},{"key":"e_1_3_3_413_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000181"},{"key":"e_1_3_3_414_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1255904"},{"key":"e_1_3_3_415_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3746"},{"key":"e_1_3_3_416_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308541"},{"key":"e_1_3_3_417_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.3.561"},{"key":"e_1_3_3_418_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta22340"},{"key":"e_1_3_3_419_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2416"},{"key":"e_1_3_3_420_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.conctc.2020.100575"},{"key":"e_1_3_3_421_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2608"},{"key":"e_1_3_3_422_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.03.017"},{"key":"e_1_3_3_423_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0754-1"},{"key":"e_1_3_3_424_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.01.007"},{"key":"e_1_3_3_425_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3655"},{"key":"e_1_3_3_426_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00430-2019"},{"key":"e_1_3_3_427_1","first-page":"17:2002695","article-title":"Phagosome-regulated mTOR Signalling during Sarcoidosis Granuloma Biogenesis","author":"Crouser ED","year":"2020","unstructured":"Crouser ED, Locke LW, Julian MW, et al. Phagosome-regulated mTOR Signalling during Sarcoidosis Granuloma Biogenesis. Eur Respir J. 2020;Sep17:2002695.","journal-title":"Eur Respir J"},{"key":"e_1_3_3_428_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.01.001"},{"key":"e_1_3_3_429_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3531"},{"key":"e_1_3_3_430_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202004-0914IM"},{"key":"e_1_3_3_431_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2011.01256.x"},{"key":"e_1_3_3_432_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S198401"},{"key":"e_1_3_3_433_1","doi-asserted-by":"publisher","DOI":"10.1186\/1869-5760-3-32"},{"key":"e_1_3_3_434_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.4.2.4"},{"key":"e_1_3_3_435_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.03.033"},{"key":"e_1_3_3_436_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.07.029"},{"key":"e_1_3_3_437_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117157"},{"key":"e_1_3_3_438_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201005-0792OC"},{"key":"e_1_3_3_439_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S25426"},{"key":"e_1_3_3_440_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104802"},{"key":"e_1_3_3_441_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24266"},{"key":"e_1_3_3_442_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24485"},{"key":"e_1_3_3_443_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100602"},{"key":"e_1_3_3_444_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.179994"},{"key":"e_1_3_3_445_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.43.7.516"},{"key":"e_1_3_3_446_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1986.tb18539.x"},{"key":"e_1_3_3_447_1","doi-asserted-by":"publisher","DOI":"10.2119\/2008-00079.Parrish"},{"key":"e_1_3_3_448_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01339"},{"key":"e_1_3_3_449_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902212"},{"key":"e_1_3_3_450_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(97)00076-0"},{"key":"e_1_3_3_451_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2008.11.053"},{"key":"e_1_3_3_452_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.169961"},{"key":"e_1_3_3_453_1","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1995.1233"},{"key":"e_1_3_3_454_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03169.x"},{"key":"e_1_3_3_455_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1549-4"},{"key":"e_1_3_3_456_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-0383"},{"key":"e_1_3_3_457_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1905"},{"key":"e_1_3_3_458_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.2369"},{"key":"e_1_3_3_459_1","doi-asserted-by":"publisher","DOI":"10.2174\/1566524011313050016"},{"key":"e_1_3_3_460_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep38308"},{"key":"e_1_3_3_461_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2921"},{"key":"e_1_3_3_462_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.11.001"},{"key":"e_1_3_3_463_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2012.06667.x"},{"key":"e_1_3_3_464_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047559"},{"key":"e_1_3_3_465_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0700-0"},{"key":"e_1_3_3_466_1","doi-asserted-by":"publisher","DOI":"10.17116\/terarkh201587239-44"},{"key":"e_1_3_3_467_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15426"},{"issue":"2","key":"e_1_3_3_468_1","first-page":"106","article-title":"Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study","volume":"32","author":"Baughman RP","year":"2015","unstructured":"Baughman RP, Culver DA, kovi V, et al. Placenta-derived mesenchymal-like cells (PDA-001) as therapy for chronic pulmonary sarcoidosis: a phase 1 study. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32(2):106\u2013114.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_3_3_469_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010278"},{"key":"e_1_3_3_470_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.08.012"},{"key":"e_1_3_3_471_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702874"},{"key":"e_1_3_3_472_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.2.642"},{"key":"e_1_3_3_473_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705606"},{"key":"e_1_3_3_474_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00136112"},{"key":"e_1_3_3_475_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2017.01.001"},{"key":"e_1_3_3_476_1","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2012.689854"},{"key":"e_1_3_3_477_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1613723"},{"key":"e_1_3_3_478_1","unstructured":"FDA Warns About Stem Cell Therapies 2017 [updated 09\/03\/2019 cited 2020 September 24]. https:\/\/www.fda.gov\/consumers\/consumer-updates\/fda-warns-about-stem-cell-therapies"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2021.1878024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:38:36Z","timestamp":1770417516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2021.1878024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,31]]},"references-count":480,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1080\/17512433.2021.1878024"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2021.1878024","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,31]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}